San Antonio Breast Cancer Symposium, December 5-9, San Antonio Breast Cancer Symposium, December 5-9, 2017
|
|
|
- Aileen Holland
- 6 years ago
- Views:
Transcription
1 San Antonio Breast Cancer Symposium, December 5-9, 2017 Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline/cyclophosphamide for patients with early breast cancer GBG69 Andreas Schneeweiss, Christian Jackisch, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Christian Schem, Hermann Wiebringhaus, Sherko Kümmel, Kerstin Rhiem, Mathias Warm, Peter A. Fasching, Marianne Just, Claus Hanusch, John Hackmann, Jens Uwe Blohmer, Bernd Gerber, Jenny Furlanetto, Gunter von Minckwitz, Valentina Nekljudova, Sibylle Loibl, Michael Untch - A joint study of the AGO Breast and the German Breast Group -
2 Core biopsy (before study entry) Surgery Study Design San Antonio Breast Cancer Symposium, December 5-9, 2017 N = 1200 Arm A R 1:1 12 weeks 12 weeks Arm B STRATIFICATION FACTORS: HER2+/HR- vs. HER2+/HR+ vs. HER2-/HR- vs. HER2-/HR+ Ki67 ( 20% vs. >20%) SPARC (positive vs. negative) Paclitaxel 80 mg/m 2 weekly Nab-paclitaxel 150 mg/m 2 weekly The dose was reduced to 125 mg/m 2 after recruitment of 464 patients Epirubicin 90 mg/m 2 Cyclophosphamide 600 mg/m 2 HER2 positive patients: Trastuzumab 8 mg/kg (loading dose) 6 mg/kg Pertuzumab 840 mg (loading dose) 420 mg Untch et al. Lancet Oncol 2016
3 Main Eligibility Criteria Unilateral or bilateral primary breast cancer Stages ct2 - ct4a-d ct1c and additional high risk cn+ or pn SLN+ or ER-neg and PR-neg or Ki67 > 20% or HER2-positive Central testing for HER2, HR, Ki67, and SPARC 1 1 Lindner J et al. Ann Oncol 2015
4 Study Endpoints San Antonio Breast Cancer Symposium, December 5-9, 2017 Primary endpoint: pcr rate (ypt0 ypn0) Secondary efficacy endpoints (overall and according to stratified subpopulations): disease-free survival (DFS) distant disease-free survival (DDFS) overall survival (OS)
5 Patient and tumor characteristics (baseline) Paclitaxel N=600 (%) Nab-paclitaxel N=606 (%) Overall N=1204 (%) Age (median, yrs ) 48 (22-76) 49 (21-75) 49 (21-76) Palpable tumor size (median, mm) 30 (5-150) 30 (4-150) 30 (4-150) ct3 / 4 (palpation) 86 (16.5) 81 (15.8) 167 (16.2) cn+ 265 (45.1) 275 (46.3) 540 (45.7) Ki67 >20% 415 (69.2) 418 (69.0) 833 (69.1) SPARC positive (IRS 6-12) 94 (15.7) 97 (16.0) 191 (15.9) Grade (56.3) 319 (52.6) 657 (54.5) Breast cancer subtype TNBC 137 (22.8) 139 (22.9) 276 (22.9) HER2-negative / HR-positive 266 (44.3) 268 (44.2) 534 (44.3) HER2-positive / HR-positive 149 (24.8) 140 (23.1) 289 (24.0) HER2-positive / HR-negative 48 (8.0) 59 (9.7) 107 (8.9) Untch et al. Lancet Oncol 2016
6 Primary Endpoint: pcr (ypt0 ypn0) 70% 60% 50% 40% 30% 20% 10% 0% 29% Paclitaxel Δ pcr 9% p< % Nab-paclitaxel N=600 N=606 The substitution of solvent-based paclitaxel (P) with nab-paclitaxel (np) as neoadjuvant chemotherapy significantly increased the pathological complete response rate (pcr; ypt0 ypn0) overall from 29% to 38% (p<0.001). The largest pcr improvement of absolute 22% (from 26% to 48%; p<0.001) was achieved in patients with TNBC. It has not yet been shown whether this will translate into an improved survival. Untch et al. Lancet Oncol 2016
7 Power Calculation San Antonio Breast Cancer Symposium, December 5-9, 2017 The analysis of DFS (and other time-to-event endpoints) was planned to be performed after 248 events had occurred. In this case the log-rank test would have 80% power to detect an improvement of the 5 year DFS from 75% to 81.8% (HR=0.70) with a 2- sided significance level of α=0.05. The cut-off date of this analysis was November 16 th At that time, 244 confirmed events were in the database with a median follow-up of 49 months (IQR ).
8 Disease-Free Survival San Antonio Breast Cancer Symposium, December 5-9, yrs Δ 6.4% Log rank p= P-EC 141/600 events np-ec 141/ /606 events + Censored np-ec 103/606 events + Censored Median follow-up of 49 months (IQR ) HR (np-ec vs. P-EC) = 0.69 (95% CI ) Number needed to treat (NNT; 3yrs) = 16 pts DFS rates (estimated): Time P-EC 95% CI, P-EC np-ec 95% CI, np-ec 3 yrs 80.7% ( ) 87.1% ( ) 4 yrs 76.2% ( ) 83.5% ( )
9 Disease-Free Survival per Subtype TNBC HR+HER2-3yr 83.1% 4yr 78.7% 3yr 86.3% 4yr 80.8% 3yr 73.4% 4yr 68.6% 3yr 78.6% 4yr %
10 Forest Plot: Disease-Free Survival
11 Overall Survival: Overall HR (np-ec vs. P-EC) = 0.83 (95% CI ) Log rank p= P-EC 72/600 deaths np-ec 61/606 deaths + Censored OS rates (estimated): Time P-EC 95% CI, P-EC np-ec 95% CI, np-ec 3 yrs 91.1% ( ) 92.3% ( ) 4 yrs 87.0% ( ) 89.6% ( ) TNBC
12 Surrogate Value of pcr (exploratory analysis) Disease-Free Survival Overall Survival p=0.941 p=0.495 p=0.328 p=0.012 v v
13 Summary San Antonio Breast Cancer Symposium, December 5-9, 2017 GeparSepto demonstrates a significantly improved DFS when patients received nab-paclitaxel instead of paclitaxel (HR=0.69, 95% CI [ ; log rank p=0.0044). A similar treatment effect was observed for patients with TNBC and HR+/HER2- tumors. The interaction with Ki67 suggests that nab-paclitaxel generates a long term benefit in particular in tumors with lower proliferation. Irrespective of the treatment group, patients achieving a pcr had a significantly better DFS. Patients without pcr have a significantly better DFS with nab-paclitaxel than paclitaxel.
14 Acknowledgements San Antonio Breast Cancer Symposium, December 5-9, 2017 All patients and their families Study teams at the 69 GeparSepto sites Team at GBG Headquarters Team of Charité for central pathology GBG / AGO-B Steering Committee and the study chairs Celgene and Roche for financial and drug support Visit for slide download
Lo Studio Geparsepto. Alessandra Fabi Oncologia Medica 1
Lo Studio Geparsepto Alessandra Fabi Oncologia Medica 1 nab-paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto GBG 69): A Randomised, Phase III Trial
Point of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
Overview of nab-paclitaxel in Breast Cancer
Overview of nab-paclitaxel in Breast Cancer William J. Gradishar MD FASCO FACP Betsy Bramsen Professor of Breast Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School
Was gynäkologische OnkologInnen über Erblichkeit wissen sollten. 9. Brustkrebskongress Köln und Niederrhein 2016
Was gynäkologische OnkologInnen über Erblichkeit wissen sollten Rita K. Schmutzler, Universitätsklinik Köln Koordinatorin des Konsortiums Familiärer Brust- und Eierstockkrebs 9. Brustkrebskongress Köln
GBG/AGO-B study groups
Prediction of pathological complete response (pcr) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC Results from GeparSixto. Gunter
AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
AGO e. V. in der DGGG e.v. sowie in der DKG e.v. Guidelines Breast Version 2015.1 www.ago-online.de Disease-Free and Overall Survival in Metastatic Breast Cancer AGO e. V. in der DGGG e.v. sowie in der
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
Breast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
Trial record 1 of 1 for: Denosumab as an add-on Neoadjuvant Treatment (GeparX) (GeparX)
This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
Locally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
Role of chemotherapy in BRCA and Triple negative breast cancer. Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos
Role of chemotherapy in BRCA and Triple negative breast cancer Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos Association between TNBC & germline mutations in BRCA 1/2 TNBC is
Novel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
ADAPT: Her 2+/ HR - S. Kümmel Brustzentrum Kliniken Essen-Mitte
American Society of Clinical Oncology Jun 2016 ADAPT: Her 2+/ HR - S. Kümmel Brustzentrum Kliniken Essen-Mitte American Society of Clinical Oncology Jun 2016 Final analysis of the WSG- ADAPT HER2+/HR-
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
Triple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
Neoadjuvant (Primary) Systemic Therapy
Diagnosis and Treatment of Patients with Primary and Metastatic reast Cancer Neoadjuvant (Primary) Systemic Therapy Neoadjuvant Systemic Therapy Versions 2002 2017: auerfeind / lohmer / Costa / Dall /
A view from the Oncology Clinic. Andrew Tu7 Consultant Clinical Oncologist
A view from the Oncology Clinic Andrew Tu7 Consultant Clinical Oncologist Our pa'ents have become much more aware and are driving a changing demand Before surgery: MRI for contralateral BC; neoadjuvant
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
VOLUME 30 NUMBER 15 MAY 20 2012 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic
What to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
Breast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
ADAPT. Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
ADAPT Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer Therapieindikation gesteuert durch prognostische Information
XII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
NeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cortazar P, Zhang L, Untch M, et al. Pathological
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
Hofmann et al. Hofmann et al. Trials 2013, 14:261
WSG ADAPT adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center,
Neoadjuvant chemotherapy as a research model
Neoadjuvant chemotherapy as a research model Prof. Dr. Sibylle Loibl Co-Chair of the German Breast Group Sana Klinikum Offenbach Heilung durch Innovation, Kompetenz und Partnerschaft DFS and OS after neoadjuvant
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
Triple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
Lecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
In Honour of Dr. Neera Patel
In Honour of Dr. Neera Patel Residual Cancer Burden (RCB) vs Pathologic Complete Response (pcr) as an End-point W. Fraser Symmans, M.D. Professor of Pathology UT M.D. Anderson Cancer Center Pathologic
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
Novel Preoperative Therapies for HER2-Positive Breast Cancer
Key Findings to Date in the Neoadjuvant Therapy of H2+ Breast Cancer Novel Preoperative Therapies for H2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive
Advanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
Nadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
Treatment of Early-Stage HER2+ Breast Cancer
Treatment of Early-Stage HER2+ Breast Cancer Chau T. Dang, MD Chief, MSK Westchester Medical Oncology Service Breast Medicine Service Memorial Sloan Kettering Cancer Center Disclosures I have research
Update on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
Update on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
Oncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
Use of Taxanes in Older Breast Cancer Patients
SIOG Guidelines Update 2014: Use of Taxanes in Older Breast Cancer Patients Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Fundamental steps Task Force (TF) on
original article introduction original article
Annals of Oncology 22: 1999 2006, 2011 doi:10.1093/annonc/mdq713 Published online 7 March 2011 PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
Updates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
HER2-Targeted Rx. An Historical Perspective
HER2-Targeted Rx An Historical Perspective Trastuzumab: Front Line Rx for MBC Median 20.3 v. 25.1 mo P = 0.046 HR 0.8 65% of control patients crossed over Slamon D, et al. N Engl J Med, 2001; 344:783 Trastuzumab:Front-line
Introduction. Approximately 20% of invasive breast cancers
Introduction Approximately 2% of invasive breast cancers overexpress HER2 The current standard of care for neoadjuvant therapy is dual-targeted therapy with trastuzumab and pertuzumab plus chemotherapy
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
ESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
HER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
Rethinking neoadjuvant therapy: neoadjuvant therapy as a platform for drug development in HER2 positive breast cancer
2016.04.29 GBCC luncheon symposium Rethinking neoadjuvant therapy: neoadjuvant therapy as a platform for drug development in HER2 positive breast cancer Seoul National University Bundang Hospital Seoul
The next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
(Neo) Adjuvant systemic therapy for HER-2+ EBC
(Neo) Adjuvant systemic therapy for HER-2+ EBC F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESMO Board of Directors & NR Committee Chair ESO Breast Cancer Program
Novel Chemotherapy Agents for Metastatic Breast Cancer. Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX
Novel Chemotherapy Agents for Metastatic Breast Cancer Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Center Dallas, TX New Chemotherapy Agents in Breast Cancer New classes of drugs Epothilones Halichondrin
EARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
Taking NeoadjuvantTreatment into the Clinic
Taking NeoadjuvantTreatment into the Clinic The Data and the Challenges Karen A Gelmon MD FRCPC Professor Medicine University of British Columbia Medical Oncologist BC Cancer Agency NeoadjuvantTherapy
Triple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany
Triple-Negative Breast Cancer Time to Slice and Dice? Carsten Denkert, MD Charité University Hospital Berlin, Germany Triple-Negative Breast Cancer (TNBC) 2018 Presentation Outline The molecular heterogeneity
Systemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
Trial record 1 of 1 for:
This site became the new ClinicalTrials.gov on June 19th. Learn more. We will be updating this site in phases. This allows us to move faster and to deliver better services. Show less IMPORTANT: Listing
Update HER2. Rupert Bartsch. Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna
Update HER2 Rupert Bartsch Department of Medicine 1, Clinical Division of Oncology Comprehensive Cancer Center Vienna Medical University of Vienna HER2: A Unique Story of Success Analysis of outcome in
10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
Xiaosong Chen 1, Guolin Ye 2, Chenfang Zhang 3, Xinzheng Li 4, Kunwei Shen 1. Original Article. Abstract
Original Article Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant
that the best available evidence has not demonstrated that pcr can predict long-term outcomes in the neoadjuvant setting.
pcr in one arm of a randomized clinical trial comparing two neoadjuvant chemotherapies predicts for improved event-free or overall survival in that arm of the clinical trial. perc noted that the NeoALTTO
The Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
Rigshospitalet. Danish Breast Cancer Cooperative Group DBCG. Neo-adjuverende medicinsk behandling. Bent Ejlertsen. 16 th ACTA ONCOLOGICA SYMPOSIUM
DBCG Neo-adjuverende medicinsk behandling Bent Ejlertsen 16 th ACTA ONCOLOGICA SYMPOSIUM Baggrund; neoadjuverende behandling Eneste mulighed hos patienter med inoperabel brystkræft. Af Bonadonna udvidet
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
Systemtherapie des primären Mammakarzinoms
Systemtherapie des primären Mammakarzinoms G. Gitsch E. Stickeler St. Kassian 2016 Themenschwerpunkte I Adjuvante Therapie Luminal A Tumoren und CHT Benefit (DBCG77B 25 Jahre Follow-up) HERA (10 Jahre
Early Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
Adjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid
Alternativas terapéuticas en fenotipo triple negativo Javier Cortes, Hospital Universitario Ramon y Cajal, Madrid Vall d Hebron Institute of Oncology (VHIO), Barcelona Triple Negative Breast Cancer Immunohistochemistry
Non-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
Breast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
Systemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
The HERA Study Team. Presented by Ian E. Smith
Trastuzumab Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer (HERA Trial): Disease-Free and Overall Survival after 2 Year Median Follow-Up The HERA Study Team Presented by Ian E. Smith
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
Postoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
William J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
Research Article Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years
Oncology Volume 2016, Article ID 4324863, 5 pages http://dx.doi.org/10.1155/2016/4324863 Research Article Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma
Interviews are based on data presented at the 2012 American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago, Illinois* *PeerVoice is an independent publisher of conference news and
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
Adjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients www.agoonline.de
Targeting the PI3 kinase mtor pathway in breast cancer. Dr Nicholas Turner. Madrid 2014
Targeting the PI3 kinase mtor pathway in breast cancer Dr Nicholas Turner Madrid 2014 Relevant disclosures Honoraria and/or Research funding Novartis AstraZeneca Roche Targeting PI3 kinase mtor pathway
2014 San Antonio Breast Cancer Symposium Review
2014 San Antonio Breast Cancer Symposium Review HER2 Positive Disease 01-10-2015 Elisavet Paplomata, MD Assistant Professor Hematology & Medical Oncology Emory University Winship Cancer Institute S6-01